Clovis hit by bladder cancer fail for RubracaClovis Oncology’s hopes of a carving out a niche for its PARP inhibitor Rubraca in bladder cancer, away Share XClovis hit by bladder cancer fail for Rubracahttps://pharmaphorum.com/news/clovis-hit-by-bladder-cancer-fail-for-rubraca/
J&J gets US okay for first targeted bladder cancer drugJohnson & Johnson’s Balversa has become the first targeted therapy for bladder cancer after an FDA approval at Share XJ&J gets US okay for first targeted bladder cancer drughttps://pharmaphorum.com/news/jj-gets-us-okay-for-first-targeted-bladder-cancer-drug/
Janssen CAR-T is Priority Medicine in EU, and moreEuropean regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage Share XJanssen CAR-T is Priority Medicine in EU, and morehttps://pharmaphorum.com/views-analysis-oncology/janssen-car-t-is-priority-medicine-in-eu-and-more/
EU regulators to fast-track Janssen’s multiple myeloma CAR-TEuropean regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage Share XEU regulators to fast-track Janssen’s multiple myeloma CAR-Thttps://pharmaphorum.com/news/eu-regulators-to-fast-track-janssens-multiple-myeloma-car-t/
Fusion raises $105m for radiopharmaceutical trialsRadiopharmaceuticals are already well established in imaging technology for a range of diseases – but their use to Share XFusion raises $105m for radiopharmaceutical trialshttps://pharmaphorum.com/news/fusion-raises-105m-towards-radiopharmaceutical-trials/
Clovis’ Rubraca is latest PARP drug showing promise in pancreatic cancerClovis Oncology’s Rubraca has become the latest PARP drug to show potential in pancreatic cancer, as pharma companies Share XClovis’ Rubraca is latest PARP drug showing promise in pancreatic cancerhttps://pharmaphorum.com/news/clovis-rubraca/
NICE recommends interim funding for Lilly’s breast cancer drugFinal draft guidance from NICE has recommended interim NHS funding for Eli Lilly’s Verzenios (abemaciclib) with fulvestrant, giving Share XNICE recommends interim funding for Lilly’s breast cancer drughttps://pharmaphorum.com/news/nice-recommends-interim-funding-for-lillys-breast-cancer-drug/
AZ’s selumetinib for rare disease gets FDA breakthrough statusAstraZeneca and Merck & Co/MSD’s selumetinib has been given a breakthrough designation from the US FDA for a Share XAZ’s selumetinib for rare disease gets FDA breakthrough statushttps://pharmaphorum.com/news/azs-selumetinib-rare-disease-fda/
Celgene-BMS merger looks good to go as shareholder backs downBristol-Myers Squibb’s mega-merger with Celgene looks set to go ahead after activist hedge fund Starboard Value backed out Share XCelgene-BMS merger looks good to go as shareholder backs downhttps://pharmaphorum.com/news/celgene-bms-merger-looks-good-to-go-as-shareholder-backs-down/
